Literature DB >> 7910658

The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells.

L J Zhang1, J E Lachowicz, D R Sibley.   

Abstract

To investigate and compare the regulatory properties of the two isoforms of the D2 dopamine receptor, we have stably expressed their cDNAs in Chinese hamster ovary (CHO) cells. Cell lines were selected that express similar levels of [3H]methylspiperone-binding activity. Both isoforms mediate a dose-dependent and pharmacologically specific inhibition of adenylyl cyclase activity in both intact cell and membrane preparations. Pretreatment of both D2L and D2S receptor-expressing cells with 100 microM dopamine produces a approximately 5-fold shift (to lower affinity) in the EC50 for dopamine inhibition of cAMP accumulation, with a 25-30% decrease in the maximum response. Dopamine treatment also results in a approximately 25% decrease in the maximum receptor binding activity of the D2S receptor-expressing cells. In contrast, the D2L receptors are up-regulated by about 2-fold in response to dopamine exposure. This difference in response between the D2S and D2L receptors is not cell line specific, inasmuch as other CHO clones expressing these isoforms show identical responses. The dopamine-induced up-regulation of D2L receptor binding is time dependent, reaching maximal levels after 10 hr (t1/2 = 2 hr). Upon removal of dopamine, the receptor binding activity returns to control levels within 20 hr. The adenylyl cyclase desensitization response is also time dependent but exhibits a slower time course (t1/2 = 5 hr) than the receptor up-regulation. Both regulatory responses are induced in a dose-dependent fashion by dopamine, albeit with different potencies (up-regulation EC50 = 100 nM, desensitization EC50 = 2 microM). These regulatory effects are pharmacologically specific, being mimicked by D2-selective agonists but not agonists of other receptor subtypes. The dopamine-induced receptor up-regulation is blocked by prior treatment of the cells with pertussis toxin and is not mimicked by cAMP analogs. Conversely, elevation of intracellular cAMP levels results in down-regulation of the D2L receptor activity. To test whether protein synthesis is required for the D2L receptor up-regulation, cycloheximide was used to block mRNA translation. This was found to completely inhibit the up-regulation of D2L binding activity; however, there was no effect on the desensitization of the adenylyl cyclase response. RNA dot-blot analyses indicate that dopamine treatment is associated with a sustained 2-fold increase in the steady state levels of D2L mRNA, whereas D2S mRNA is transiently increased by only 50%.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7910658

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

1.  Agonist-induced endocytosis and receptor phosphorylation mediate resensitization of dopamine D(2) receptors.

Authors:  Dongim Cho; Mei Zheng; Chengchun Min; Lan Ma; Hitoshi Kurose; Jae H Park; Kyeong-Man Kim
Journal:  Mol Endocrinol       Date:  2010-02-16

2.  Novel roles for β-arrestins in the regulation of pharmacological sequestration to predict agonist-induced desensitization of dopamine D3 receptors.

Authors:  C Min; M Zheng; X Zhang; M G Caron; K M Kim
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.

Authors:  F I Tarazi
Journal:  J Sci Res Med Sci       Date:  2001-10

4.  MicroRNA-9 and microRNA-326 regulate human dopamine D2 receptor expression, and the microRNA-mediated expression regulation is altered by a genetic variant.

Authors:  Sandra Shi; Catherine Leites; Deli He; Daniel Schwartz; Winton Moy; Jianxin Shi; Jubao Duan
Journal:  J Biol Chem       Date:  2014-03-27       Impact factor: 5.157

5.  The interaction between the mu opioid receptor and filamin A.

Authors:  Eric J Simon; Irma Onoprishvili
Journal:  Neurochem Res       Date:  2010-09-21       Impact factor: 3.996

6.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

7.  Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.

Authors:  Irma Onoprishvili; Eric J Simon
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

8.  Dopamine D2 receptor stimulation alters G-protein expression in rat pituitary intermediate lobe melanotropes.

Authors:  S A Sands; D S Dickerson; S J Morris; B M Chronwall
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

9.  D1-D2 dopamine receptor synergy promotes calcium signaling via multiple mechanisms.

Authors:  Lani S Chun; R Benjamin Free; Trevor B Doyle; Xi-Ping Huang; Michele L Rankin; David R Sibley
Journal:  Mol Pharmacol       Date:  2013-05-16       Impact factor: 4.436

10.  G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor.

Authors:  Yoon Namkung; Concetta Dipace; Jonathan A Javitch; David R Sibley
Journal:  J Biol Chem       Date:  2009-03-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.